DHX9 as a prognostic biomarker and its biological roles in acute myeloid leukemia.

ABSTRACT:

Background

Acute myeloid leukemia (AML) is a highly malignant hematopoietic disease, with low remission and high relapse rates, and there is currently no effective treatment except for acute promyelocytic leukemia. DExH-Box Helicase 9, a member of the DExD/H-box family of helicases, is highly expressed in some solid tumors and associated with poor prognosis. However, its role in AML has not been reported. This study aimed to investigate the clinical significance and biological roles of DHX9 in AML.

Methods

Specific gene primers and TaqMan probes were prepared to construct absolute quantitative methods for DHX9. Receiver operating characteristic curves were constructed to evaluate the diagnostic and prognostic value of DHX9. Series of shRNA-mediated DHX9 knockdown experiments

SUBMITTER: Xiong Y 

PROVIDER: S-EPMC12481950 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature